Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens

HIV Clinical Trials

Volumn 3, Issue 1, 2002, Pages 17-20

  Press, Natasha ^a   Kimel, Gil ^a   Harris, Marianne ^a   Yip, Benita ^a   Craib, Kevin J P ^a   Montaner, Julio S G ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

Highly active antiretroviral therapy; Mycophenolic acid; Salvage therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HYDROXYUREA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MALE; MEDICAL ASSESSMENT; MULTIDRUG RESISTANCE; OUTPATIENT; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 0036184724     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/B6T0-N98J-1J3M-EQPK     Document Type: Article

References (4)

1. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity
2. Hydroxyurea in the treatment of HIV-1 infection: Toxicity and side effects
3. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection
4. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo